Summary of the British transplantation society guidelines for the prevention and management of CMV disease after solid organ transplantation

Transplantation

Volumn 92, Issue 11, 2011, Pages 1181-1187

  Andrews, Peter A ^a   Emery, Vincent C ^b   Newstead, Chas ^c  

^a ST HELIER HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Cytomegalovirus; Guideline; Transplantation; Valganciclovir

Indexed keywords

AZATHIOPRINE; BENZIMIDAVIR; CALCINEURIN INHIBITOR; CIDOFOVIR; CYTOMEGALOVIRUS ANTIBODY; CYTOMEGALOVIRUS VACCINE; FOSCARNET; GANCICLOVIR; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; LEFLUNOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RAPAMYCIN; VALACICLOVIR; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ANTIVIRAL RESISTANCE; ARTICLE; BONE MARROW TRANSPLANTATION; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; ELECTROLYTE DISTURBANCE; EVIDENCE BASED MEDICINE; GENOTYPE; GRAFT SURVIVAL; GRAND MAL EPILEPSY; HEART LUNG TRANSPLANTATION; HEART TRANSPLANTATION; HUMAN; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MEDICAL DECISION MAKING; MEDICAL SOCIETY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); ORGAN TRANSPLANTATION; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; TREATMENT DURATION; UNITED KINGDOM; VIRUS LOAD;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; GANCICLOVIR; GREAT BRITAIN; HUMANS; ORGAN TRANSPLANTATION; PRACTICE GUIDELINES AS TOPIC;

EID: 81855213129     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318235c7fc     Document Type: Article

References (68)

1. http://www.bts.org.uk/transplantation/standards-and-guidelines/. Accessed July 14, 2011.
2. Uhlig K, Macleod A, Craig J, et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 70: 2058.
3. Kidney Disease Improving Global Outcomes (KDIGO) Transplant Work Group: KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9(S3): S1.
4. Berthoux F, Abramowicz D, Bradlet B, et al. European best practice guidelines for renal transplantation (Part 1). Nephrol Dial Transplant 2000; 15(suppl 7): 1.
5. http://www.renal.org/Clinical/GuidelinesSection/Post-operative-Care- Kidney-Transplant-Recipient.aspx. Accessed July14, 2011.
6. Kidney Disease Improving Global Outcomes (KDIGO) Transplant Work Group: KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9(S3): S1.
7. Patel R, Snydman DR, Rubin RH, et al. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 1996; 61: 1279.
8. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815.
9. Emery VC, Sabin CA, Cope AV, et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355: 2032.
10. Piiparinen H,Höckerstedt K, Grönhagen-Riska C, et al. Comparison of two quantitative CMV PCR tests, Cobas Amplicor CMV Monitor and TaqMan assay, and pp65-antigenemia assay in the determination of viral loads from peripheral blood of organ transplant patients. J Clin Virol 2004; 30: 258.
11. Pescovitz MD, Paya C, Humar A, et al. Valganciclovir for prevention of CMVdisease: 12 month follow up of a randomized trial of 364D+/R- transplant recipients. Am J Transplant 2003; 3(S5): 299.
12. Paya C, Humar A, Dominguez E, et al. Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611.
13. Boivin G, Goyette N, Gilbert C, et al. Valganciclovir prophylaxis is not associated with the emergence of cytomegalovirus UL97 and UL54 resistance mutations in solid organ transplant recipients: Results from a multicenter trial. Am J Transplant 2003: 3(S5): 431.
14. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228.
15. Humar A, Michaels M. AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262.
16. Blumberg EA, Hauser IA, Stanisic S, et al. Prolonged prophylaxis with valganciclovir is cost effective in reducing posttransplant cytomegalovirus disease within the United States. Transplantation 2010; 90: 1420.
17. http://www.scottishmedicines.org.uk/files/advice/valganciclovir-Valcyte- FINAL-DECEMBER-2010.doc-for-website.pdf. Accessed March 5, 2011.
18. Kalil AC, Mindru C, Florescu DF. Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: Direct and indirect treatment comparison meta-analysis. Clin Infect Dis 2011; 52: 313.
19. Avery RK. Low-dose valganciclovir for cytomegalovirus prophylaxis in organ transplantation: Is less really more? Clin Infect Dis 2011; 52: 322.
20. Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation. A randomized controlled trial. Ann Intern Med 2010; 152: 761.
21. Mattes FM, Hainsworth EG, Hassan-Walker AF, et al. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis 2005; 191: 89.
22. Buyck HC, Griffiths PD, Emery VC.Humancytomegalovirus(HCMV) replication kinetics in stem cell transplant recipients following anti- HCMV therapy. J Clin Virol 2010; 49: 32.
23. Emery VC, Hassan-Walker AF, Burroughs AK, et al. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts. J Infect Dis 2002; 185: 1723.
24. http://www.nibsc.ac.uk/spotlight/sogat/clinical-diagnostics/ past-meetings/january-2011-presentations.aspx. Accessed July 14, 2011.
25. Benedetti E, Mihalov M, Asolati M, et al. A prospective study of the predictive value of polymerase chain reaction assay for cytomegalovirus in asymptomatic kidney transplant recipients. Clin Transplant 1998; 12: 391.
26. Sagedal S, Nordal KP, Hartmann A, et al. Pre-emptive therapy of CMV pp65 antigen positive renal transplant recipients with oral ganciclovir: A randomized, comparative study. Nephrol Dial Transplant 2003; 18: 1899.
27. Stocchi R, Szydlo R, Craddock C, et al. A comparison of prophylactic vs pre-emptive ganciclovir to prevent cytomegalovirus disease after T-depleted volunteer unrelated donor bone marrow transplantation. Bone Marrow Transplant 1999; 23: 705.
28. Knzle N, Petignat C, Francioli P, et al. Preemptive treatment approach to cytomegalovirus (CMV) infection in solid organ transplant patients: Relationship between compliance with the guidelines and prevention of CMV morbidity. Transpl Infect Dis 2000; 2: 118.
29. Ketteler M, Kunter U, Floege J. An update on herpes virus infection in graft recipients. Nephrol Dial Transplant 2003; 18: 1703.
30. Hart GD, Paya CV. Prophylaxis forCMVshould now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001; 11: 73.
31. Emery VC. Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001; 11: 83.
32. Snydman DR. The case for cytomegalovirus prophylaxis in solid organ transplantation. Rev Med Virol 2006; 16: 289.
33. Singh N. Antiviral drugs for cytomegalovirus in transplant recipients: Advantages of preemptive therapy. Rev Med Virol 2006; 16: 281.
34. Baillie GM. Prevention of cytomegalovirus disease in solid organ transplant patients: Prophylactic versus preemptive therapy. Am J Health Syst Pharm 2006; 63(19 suppl 5): S10.
35. Fishman JA, Emery V, Freeman R, et al. Cytomegalovirusintransplantation- Challenging the status quo. Clin Transplant 2007; 21: 149.
36. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66: 329.
37. Kliem V, Fricke L, Wollbrink T, et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial. Am J Transplant 2008; 8: 975.
38. Pass RF, Zhang C, Evans A, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009; 360: 1191.
39. Griffiths PD, Stanton A, McCarrell E, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: A phase 2 randomised placebo-controlled trial. Lancet 2011; 377: 1256.
40. Dunn DL, Mayoral JL, Gillingham KJ, et al. Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir. Transplantation 1991; 51: 98.
41. Harbison MA, De Girolami PC, Jenkins RL, et al. Ganciclovir therapy of severe cytomegalovirus infections in solid-organ transplant recipients. Transplantation 1988; 46: 82.
42. Reed EC, Wolford JL, Kopecky KJ, et al. Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized, placebo- controlled trial. Ann Intern Med 1990; 112: 505.
43. Reed EC. Treatment of cytomegalovirus pneumonia in transplant patients. Transplant Proc 1991; 23(S1): 8-12.
44. Emanuel D, Cunningham I, Jules-Elysee K, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high dose intravenous immunoglobulin. Ann Intern Med 1988; 109: 777.
45. Asberg A, Humar A, Rollag H, et al. VICTOR Study Group. Oral valganciclovir is non-inferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7: 2106.
46. George MJ, Snydman DR, Werner BG, et al. Use of ganciclovir plus cytomegalovirus immune globulin to treat CMV pneumonia in orthotopic liver transplant recipients. Transplant Proc 1993; 25: 22.
47. Falgas ME, Snydman DR, Griffith J, et al. Clinical and epidemiological predictors of recurrent cytomegalovirus disease in orthotopic liver transplant recipients. Clin Infect Dis 1997; 25: 314.
48. van den Berg AP, van Son WJ, Haagsma EB, et al. Prediction of recurrent cytomegalovirus disease after treatment with ganciclovir in solidorgan transplant recipients. Transplantation 1993; 55: 847.
49. Manez R, Kusne G, Green M, et al. Incidence and risk factors associated with the development of cytomegalovirus disease after intestinal transplantation. Transplantation 1995; 59: 1010.
50. Humar A, Uknis M, Carlone-Jambor C, et al. Cytomegalovirus disease recurrence after ganciclovir treatment in kidney and kidney-pancreas transplant recipients. Transplantation 1999; 67: 94.
51. Boivin G, Erice A, Crane DD, et al. Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients withCMV viraemia after antiviral prophylaxis. J Infect Dis 1993; 168: 332.
52. Slavin MA, Bindra RR, Gleaves CA, Pettinger MB, Bowden RA. Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients. Antimicrob Agents Chemother 1993; 36: 1360.
53. Jordan A, Bhorade SM, Lurain NS, et al. Emergence of ganciclovir resistant cytomegalovirus in lung transplant recipients. Transplant 2001, Chicago, IL, May 11-16, 2001.
54. Li F, Kenyon KW, Kirby KA, Fishbein DP, et al. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. Clin Infect Dis 2007; 45: 439.
55. Lurain NS, Bhorade SM, Pursell KJ, et al. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J Infect Dis 2002; 186: 760.
56. Asberg A, Humar A, Jardine AG, et al. VICTOR Study Group. Longterm outcomes ofCMVdisease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009; 9: 1205.
57. Nichols WG, Corey L, Gooley T, et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: Risk factors, correlation with DNA load, and outcomes. Blood 2001; 97: 867.
58. Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010; 23: 689.
59. Chou SW. Cytomegalovirus drug resistance and clinical implications. Transpl Infect Dis 2001; 3(S2): 20.
60. Erice A. Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev 1999; 12: 286.
61. Rubin RH. Prevention and treatment of cytomegalovirus disease in heart transplant patients. J Heart Lung Transplant 2000; 19: 731.
62. Levi ME, Mandava N, Chan LK, et al. Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide. Transpl Infect Dis 2006; 8: 38.
63. Mossad SB, Avery RK. Second look at leflunomide "failure" to control cytomegalovirus infection in the setting of renal failure. Transpl Infect Dis 2007; 9: 260; author reply 260.
64. Battiwalla M, Paplham P, Almyroudis NG, et al. Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. Transpl Infect Dis 2007; 9: 28.
65. Delgado JF, Manito N, Almenar L, et al. Risk factors associated with cytomegalovirus infection in heart transplant patients: A prospective, epidemiological study. Transpl Infect Dis 2011; 13: 136. doi: 10.1111/j.1399-3062.2010.00573.x.
66. Steininger C. Novel therapies for cytomegalovirus disease. Recent Pat Antiinfect Drug Discov 2007; 2: 53.
67. Eid AJ, Razonable RR.Newdevelopments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 2010; 70: 965.
68. Peggs KS. Adoptive T cell immunotherapy for cytomegalovirus. Expert Opin Biol Ther 2009; 9: 725.